FibroBiologics (FBLG) announced it received a favorable determination from a Nasdaq Hearings Panel granting an extension to regain compliance for the continued listing of the Company’s common stock on The Nasdaq Capital Market.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Faces Nasdaq Delisting Review After Noncompliance
- FibroBiologics issued Canadian patent covering treatment of Cachexia
- FibroBiologics CEO says 2026 ‘will be about execution’
- FibroBiologics announces preclinical results for FSdC
- FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split